|
Get On Board With Us!! Sign Up Today And Let Us Show You What We Can Do!! ECOB "EcoBlu Products Signs First Authorized Affiliate"
(M2 PressWIRE Via Acquire Media NewsEdge) STOCK MARKETING INC PRESENTS : OTCBB: ECOB) EcoBlu Products, Inc., (PINKSHEETS: CDIV) Cascadia Investments, Inc., (OTCBB: BKYI) BIO-key International, Inc., (OTCBB: FLXT) Flexpoint Sensor Systems, Inc., (OTCBB: ECTE) Echo Therapeutics, Inc., (OTCBB: CGXP) Ceragenix Pharmaceuticals, Inc.
www.StockMarketingInc.com
To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com
email us!! info@StockMarketingInc.com or call 1-866-583-8960
------------------------------------------------------------------------------------------------------------------------------------------------------------
(OTCBB: ECOB - EcoBlu Products, Inc.)
LATEST NEWS!!
EcoBlu Products Signs First Authorized Affiliate
VISTA, Calif., Jan 6, 2010 -- EcoBlu Products, Inc., (OTCBB:ECOB) announced today that it has signed Calvert Company, Inc. of Vancouver, WA as its first authorized affiliate. Calvert will manufacture private label glued laminated beams for EcoBlu Products, and will offer to the market its complete line of glued laminated beams including curved and arched, straight, fabricated trusses and custom products; all protected with EcoBlu's BLUWOOD(TM) and FRC(TM) (Fire Retardant Coating) technology.
"As a 60 year old manufacturer of glulams, Calvert has a long reputation for quality products and have recognized the tremendous value EcoBlu's BLUWOOD(TM) and FRC(TM) technology adds to their line," said Steve Conboy, President and CEO of EcoBlu Products. "We are proud to have them on board and expect them to have a strong impact with us nationally and overseas through their exports," added Conboy.
Calvert will operate a licensed factory application center for EcoBlu's BLUWOOD(TM) and FRC(TM) coatings and distribute their product line as well as other covered structure wood components coated with licensed technology.
Glulam production in the United States and Canada for the first half of 2008 was approximately 148 million board feet or approximately $885 million dollars, as reported by the APA.
About EcoBlu Products, Inc.
EcoBlu Products, Inc. is a manufacturer of proprietary wood products coated with an eco-friendly chemistry that protects against mold, fungus, rot-decay, wood ingesting insects, termites and fire with EcoBlu's FRC(TM) technology (Fire Retardant Coating). EcoBlu products utilizing BLUWOOD(TM) and FRC(TM) technology is the ultimate in wood protection, preservation, and fire safety to building components constructed of wood; from joists, beams and paneling, to floors and ceilings.
The Company is committed to the development, marketing and sales of environmentally-responsible building materials. EcoBlu products are ready to deliver the winning edge to builders and the environment with its sustainable green product line.
------------------------------------------------------------------------------------------------------------------------------------------------------------
(PINKSHEETS: CDIV - Cascadia Investments, Inc.)
LATEST NEWS!!
Cascadia Investments, Inc. Announces Acquisition of CustomFlashGames.com
TACOMA, WA, Jan 07, 2010 -- (PINKSHEETS: CDIV) Cascadia announced today that it has acquired a majority stake in CustomFlashGames.com. CustomFlashGames.com creates ready-to-launch Flash games for clients as well as multiple in-house projects. Cascadia plans to expand CustomFlashGames.com into an online marketplace, which is rapidly expanding. This latest acquisition also includes several other sites currently in development plus multiple Facebook applications. comScore, a leading marketing research company that provides marketing data and services to many of the Internet's largest businesses, estimates that more than 1 billion people play online games every month.
Cascadia Investments, Inc. is a publicly traded, internet development company operating in the Pacific Northwest. The company's principal objective is to create equity and long-term earnings growth through the acquisition and development of cutting edge internet properties.
------------------------------------------------------------------------------------------------------------------------------------------------------------
(OTCBB: BKYI - BIO-key International, Inc.)
LATEST NEWS!!
BIO-key(R) Launches TruDonor ID(TM), the First SaaS (Software as a Service) Biometric Identification Solution
Organizations of Any Size Can Quickly Deploy This Identity Solution Delivered as a Cloud-Based Hosted Service
WALL, N.J., Jan 07, 2010 -- BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader in finger-based biometric identification solutions, today announced the launch of TruDonor ID, a fully hosted identity solution tailored to address the needs of the blood collection industry.
With TruDonor ID, blood centers of any size now have a fast, convenient and accurate method to positively identify donors. Following on earlier successes in the blood donor identification market, BIO-key's introduction of this secure SaaS (Software as a Service) donor ID solution provides an affordable, fully supported, web based solution that staff can access from anywhere and at anytime.
Leveraging BIO-key's award winning biometric identification software, TruDonor ID accurately identifies donors without the need for them to produce IDs or remember donor ID numbers. This virtually eliminates the potential of misidentification of donors and it reduces the time and errors associated with staff validating identities and manually entering information. TruDonor ID interfaces to existing blood management platforms or can operate as a standalone identity solution.
"This is a huge breakthrough not only for blood centers but for the biometric identification industry as well," stated Mike DePasquale, CEO of BIO-key International. "Offering TruDonor ID as a SaaS solution eliminates one of the biggest hurdles faced by every blood center - costly IT expenditures on equipment, staff and maintenance. With TruDonor ID, blood centers have secure 24/7 access to their donor database on a superior computing environment supported by expert technicians." Mr. DePasquale also noted that "deployment times are far shorter since we eliminate the typical implementation learning curve associated with installing a licensed software solution. This is a first for the Identity Management Industry, a first for BIO-key and the beginning of a whole new era in the deployment of advanced security solutions including finger biometrics." In June of 2009 IDC and Gartner Research both issued growth projections of over 20% annually for the SaaS market. IDC reported that "The harsh economic climate will actually accelerate the growth prospects for the software as a service (SaaS) model as vendors position offerings as right-sized, zero-CAPEX alternatives to on-premise applications." Additionally IDC found "The percentage of U.S. firms which plan to spend at least 25% of their IT budgets on SaaS applications will increase from 23% in 2008 to nearly 45% in 2010." About BIO-key BIO-key International, Inc., headquartered in Wall, New Jersey, develops and delivers advanced identification solutions to commercial and government enterprises, integrators, and custom application developers. BIO-key's award winning, high performance, scalable, cost-effective and easy-to-deploy biometric finger identification technology accurately identifies and authenticates users of wireless and enterprise applications. Our solutions are used in local embedded OEM products as well as some of the world's largest identification deployments to improve security, guarantee identity, and help reduce identity theft. BIO-key's technology is offered directly or by market leading partners around the world. (http://www.bio-key.com)
------------------------------------------------------------------------------------------------------------------------------------------------------------
(OTCBB: FLXT - Flexpoint Sensor Systems, Inc.)
LATEST NEWS!!
Flexpoint Announces Use of Sensors for Airline and Aircraft Applications
DRAPER, Utah, Jan 07, 2010 -- Flexpoint Sensor Systems, Inc. (OTCBB:FLXT) announced that they are working with a major airline manufacturer in the development of a "poppet valve" to be utilized in the hydraulic systems of aircraft. The valve will utilize the Bend Sensor(R) in its design. The company is also working with the manufacturer of aircraft flight simulators on the incorporation of a Bend Sensor(R) as a Passenger Presence Detection device in simulators used for pilot training.
Poppet valves are of very robust and resilient construction for use in directional control valves. They are usually very tolerant of typical contaminants (rust, scale, etc). This type of valve construction is typically characterized as being a high flow, fast acting design. The bend sensor is ideally suited for this type of application because of its ability to handle exposure to a wide variety of liquids and harsh environments. The single layer construction, overall durability, and its chemical resistant properties make the Bend Sensor(R) a good solution for this type of application.
The application of the Bend Sensor(R) in the simulator seems to be an ideal fit since the Bend Sensor(R) has already proven itself as a reliable and dependable Passenger Presence Detection device and is currently being used for this application in emergency vehicles.
Clark Mower, President of Flexpoint Sensor Systems, stated, "We are pleased to be working with two separate companies on the application of our Bend Sensor(R) technology in the airline/aircraft industry. Initial testing with both companies has gone well. We are currently in our second design iteration with both applications and expect further development to take place over the next few months. The airline manufacturing company we are working with is a significant and experienced player in the market and has the capacity to incorporate a large number of valves in both new aircraft and potentially as a retrofit replacement in existing aircraft. There are multiple valves in each system and aircraft have redundant systems for safety purposes with tens of thousands of airplanes in the US alone. The simulator market is much smaller, but has a very specialized usage and broad exposure in the industry."
------------------------------------------------------------------------------------------------------------------------------------------------------------
(OTCBB: ECTE - Echo Therapeutics, Inc.)
LATEST NEWS!!
Echo Therapeutics to Present at OneMedForum 2010 Emerging Company Finance Conference
FRANKLIN, Mass., Jan 07, 2010 -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a diabetes management company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that Patrick T. Mooney, M.D., Chairman and Chief Executive Officer, will present at the OneMedPlace Finance Forum 2010 at 11.45 a.m. (PT) on Wednesday, January 13, 2010 at The Sir Francis Drake Hotel in San Francisco, CA.
Company management will be available for one-on-one meetings on January 12th and 13th. Please contact Brett Maas at (646) 536-7331 or brett@haydenir.com to request a meeting.
"Building on the significant positive momentum of 2009, we believe that we have set the stage for an exciting and productive 2010, as we enter the year with most of the initial product development work behind us and two significant strategic partnerships in place," commented Patrick T. Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics. "We are now focused on completing milestone events, including key clinical trials, which will enable us to begin generating revenue. We anticipate near-term revenue for Echo from the royalties on Prelude disposables and lidocaine sales by Ferndale Pharma Group in the topical anesthetic market in the US and UK during 2010. Additionally, we are positioned to be 'first-to-market' with tCGM in the hospital critical care market and we estimate that the hospital market opportunity for continuous glucose monitoring is greater than $1 billion. Finally, we plan to develop our Symphony system for use in the consumer market, providing additional upside potential and partnership possibilities in this more than $10 billion market opportunity. We are excited to share our vision and discuss our future opportunities with investors at this conference." About the OneMedForum 2010 Held annually in San Francisco, the OneMedPlace Finance Forum was created to connect emerging healthcare and life science companies with investors and strategic partners. Over 100 company presentations will occur by some of the most promising - and typically least recognized - companies in the world. Recognizing the impacts and opportunities connected to healthcare reform and the stimulus package, the conference has added a third day dedicated to Health Information.
More information is available at http://www.onemedplace.com/onemedforum/index.php.
About Echo Therapeutics Echo Therapeutics is focused on medical devices and specialty pharmaceuticals. Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System for transdermal drug delivery of a wide range of novel topical reformulations of widely-used, FDA-approved products.
------------------------------------------------------------------------------------------------------------------------------------------------------------
(OTCBB: CGXP - Ceragenix Pharmaceuticals, Inc.)
LATEST NEWS!!
Ceragenix and BioPro Enter into Distribution and Supply Agreement for EpiCeram(R)
BioPro to Market and Sell in Hong Kong and Taiwan
DENVER, Jan 07, 2010 -- Ceragenix Pharmaceuticals, Inc. ("Ceragenix") (OTCB:CGXP), a medical device company focused on infectious disease and dermatology today announced that it has entered into an exclusive distribution and supply agreement (the "Agreement") with BioPro Pharmaceutical, Inc. ("BioPro"), to commercialize EpiCeram(R), a prescription topical cream for treating atopic dermatitis and other dry skin conditions, in Hong Kong and Taiwan (the "Territories").
The Agreement grants BioPro exclusivity in the Territories for the distribution and marketing of EpiCeram(R) while Ceragenix will be responsible for the manufacturing and supply of the product. BioPro is also responsible for obtaining regulatory clearance to market EpiCeram(R) in the Territories. Financial terms were not disclosed. Steven Porter Chairman and Chief Executive Officer of Ceragenix said, "We are very pleased to expand our Asian footprint for EpiCeram(R) by partnering with BioPro. We are very impressed with their capabilities and we look forward to working with them. " "We are delighted to enter into this agreement for the Distribution and Supply of Ceragenix's EpiCeram(R) for treating atopic dermatitis and other dry skin conditions. There is an unmet medical need in that use of EpiCeram(R) has been shown to be very effective in comparison with a number of steroidal based products while offering an improved margin of clinical safety" said Peter Huang, Chairman and CEO of BioPro Pharmaceutical, Inc. "The introduction of EpiCeram(R) is a terrific addition to our current line of products.
About EpiCeram(R) EpiCeram(R) is a topical cream that utilizes Ceragenix's Barrier Repair Technology. In April 2006, the FDA provided clearance to market EpiCeram(R) to improve dry skin conditions and to relieve and manage the burning and itching associated with various dermatoses including atopic dermatitis (eczema), irritant contact dermatitis, radiation dermatitis, and other dry skin conditions by maintaining a moist wound and skin environment. All of these conditions are associated with a deficient skin barrier function.
About Ceragenix Ceragenix Pharmaceuticals, Inc. is a medical device company focused on infectious disease and dermatology. The Company has two base technology platforms; Ceragenins(TM) or ("CSAs") for treatment of infectious disease and Barrier Repair for the treatment of dermatological disorders including atopic dermatitis, neonatal skin disorders and others. Ceragenin(TM) compounds are active against a broad range of gram positive and negative bacteria. We have used our Ceragenin(TM) technology to formulate Cerashield(TM)antimicrobial coatings for medical devices. All Ceragenin(TM) and Cerashield(TM) products are currently in the developmental stage. Ceragenix's patented Barrier Repair technology, invented by Dr. Peter Elias, is the platform for the development of EpiCeram(R) which is currently being marketed by Promius Pharmaceuticals (a wholly owned subsidiary of Dr. Reddy's Laboratories) in the United States, Pediapharm, Inc. in Canada and Hyphens Marketing, Ltd. in certain Southeast Asian countries under exclusive supply and distribution agreements. For additional information on Ceragenix, please visit www.ceragenix.com.
------------------------------------------------------------------------------------------------------------------------------------------------------------
About StockMarketingInc.com
StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.
((Comments on this story may be sent to info@m2.com))
(c) 2010 M2 COMMUNICATIONS
[ Back To TMCnet.com's Homepage ]
|
TMCnet LOGIN
Webinars
